Our long-term focus is the research, development, licensing, manufacturing, and worldwide sales and distribution of our important products. 22nd Century Group’s proprietary genetic engineering technology and plant breeding expertise allow us to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result of our unique technology, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels. The applications for this technology are extraordinary; in independent clinical studies, our very low nicotine (VLN) tobacco has demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$7.3 m||$529 k||$8.5 m||$12.3 m|
Revenue growth, %
|($26.2 m)||($15.6 m)||($11 m)||($11.6 m)|